Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Handelsbanken Nordic Small & Mid Cap Seminar 2024
21 slides from Vitrolife Ab's conference presentation, Jun 4, 2024
Slide 1: Handelsbanken Nordic Small & Mid Cap Seminar 2024
Handelsbanken Nordic Small & Mid Cap Seminar 2024 Bronwyn Brophy, CEO
Slide 2: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining 5-7% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years 2 *Source: World Health O
Slide 3: Improvement in treatment outcomes is needed
Improvement in treatment outcomes is needed Less than half of all embryos transferred today result in pregnancy IVF birth rates have risen for patients under 43 in the last 30 years Birth rates per embryo transferred using patient eggs by age band, 1991-2018, 2019 data 35% Under 35 30% 35-37 Birth r
Slide 4: Global access and affordability to IVF treatment is improving
Global access and affordability to IVF treatment is improving Country 2022 IVF treatments % of total China 1,045 25% Japan 511 12% USA 387 9% India 176 4% Russia 149 4% Spain 143 3% Other countries 1,746 42% Global 4,157 100% 4 Source: Combination of public sources (NPESU, CDC, SART, CARTR, JSOG, ES
Slide 5: Vitrolife Group at a glance
Integrity Mission Be the leading global partner in reproductive health, Quality striving for better treatment outcomes for patients Global presence in Employees Sales in 2023 Innovation 125 markets ~ 1,100 3,512MSEK Collaboration 5
Slide 6: Vision: Enable people to fulfill the dream of having a healthy baby
Vision: Enable people to fulfill the dream of having a healthy baby Portfolio covering every step of the IVF journey combined with best-in-class quality, service and training IVF process Prenatal & Postnatal Pretreatment 6
Slide 7: Key IVF market dynamics – How can the Vitrolife Group bring value to the ecosystem
Key IVF market dynamics – How can the Vitrolife Group bring value to the ecosystem Growth in demand Increase IVF capacity and accessibility Clinics labour and skills shortage Automation and digitalisation Consolidation of clinics Standardisation and scalability Diverse portfolio to address differenc
Slide 8: Corporate Strategy Vitrolife Group
Corporate Strategy Vitrolife Group Our values Integrity Market Growth Labour and Patient megatrends in demand skills shortage Consolidation Regionalisation empowerment Quality Vision with a purpose Long-term growth and profit-targets - 5 years ”Enable people to fulfil the dream of having a healthy b
Slide 9: Strategic Priority 1: Own the platform connecting products and services
Strategic Priority 1: Own the platform connecting products and services Lab control software is the layer connecting products and services to a platform. Consultations Pregnancy IVF cycle pathway Live-birth and treatments supervision IVF process Initial Follicle Oocyte Sperm Denudation, Embryo Cryo-
Slide 10: Why Witness?
Why Witness? Mistakes in clinics occur IVF mother: 'I love him to bits. But he's probably Mistakes that can happen: not mine' Wrong embryos created/transferred Some women fear they were implanted with somebody else's baby after IVF lab errors. Wrong gametes thawed/destroyed Mix-up of sperm Dutch IVF
Slide 11: Who is using Witness
Who is using Witness Embryologists, lab technicians, quality managers Gynaecologists, nurses, front-desk staff Complete modular software for fertility clinics User-friendly multi device interface ISO certified - safety first
Slide 12: lm N SY Q
©@Fertility lm N SY Q 7 Q coetad + storage A ~ a aN Andrology lab
Slide 13: Labels
Labels @Fertility
Slide 14: RFID Reader
RIFD Reader ©@Fertility
Slide 15: Vitrolife Group is uniquely positioned
Vitrolife Group is uniquely positioned Time Lapse EmbryoScope + Non-invasive PGTA + Witnessing Two methods for embryo evaluation PGT-M PGT-A EMBRACE 1 Time-lapse technology-based assessment 2 Genetic assessment EmbryoScope® uses AI-based algorithms to analyse full course Analysis of embryo DNA to de
Slide 16: Interim Report Q1 / 2024
Interim Report Q1 / 2024 2024-04-18 Vitrolife AB (publ) Bronwyn Brophy O’Connor, CEO Patrik Tolf, CFO
Slide 17: Strong growth in APAC and solid margins
Strong growth in APAC and solid margins First quarter Sales Organic growth Gross margin 841 MSEK 0% 57.1% (854 MSEK) -2% in SEK In local currencies (56.8%) EBITDA Operating cash flow Earnings per share 272 MSEK 198 MSEK 0.85 SEK Margin 32.4% (30.6%) (160 MSEK) (0.74 SEK) 17
Slide 18: Sales and growth per geographical segment
Sales and growth per geographical segment Americas EMEA APAC Total Organic growth* -14% -2% +19% 0% Sales (MSEK) 248 310 283 841 Share of total sales 29% 37% 34% * Organic growth in local currencies 18
Slide 19: Focus for the rest of the year
Focus for the rest of the year Priority Progress Senior Vice President North America appointed April 1st Increase share and penetration in the US & China Increased direct commercial headcount in China Increase market share in Consumables Scaled up manufacturing capabilities to meet demand Acce
Slide 20: Q/A Thank you!
Q/A Thank you! Contact: Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21
Slide 21: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, ther
Vitrolife Group — Handelsbanken Nordic Small & Mid Cap Seminar 2024 on 6ix